Taking You Cultures to New Dimensions
I am pleased to feature Dr. Claudia Zylberberg, President and CEO of Akron Biotech, in this edition of “News Behind the News”. She is an expert and innovator in providing tools and methods for the discovery and development of cell based therapies. This starts with potent cell based assays and culminates with the ability to provide GMP produced reagents to support animal testing and other pre-clinical trial drug discovery processes.
Scientist and Entrepreneur a Synopsis
Claudia has a background that uniquely positions her to understand and address the growing needs and requirements of the basic and drug discovery research community. This includes researchers using stem cells as for discovery and potential therapies. Here’s an overview.
With a PhD in Biotechnology from the University of British Columbia and University of Buenos Aires, Claudia has over 25 years of experience in the international biopharmaceutical industry. At NABI Biopharmaceuticals, she and her team developed and scaled plasma-derived products and recombinant vaccines. This included harmonizing products between EMEA and FDA. She has authored and co-authored many scientific articles and developed several commercial products for use in the field of cellular biology. She has also authored a children’s book on genetics and has several patent pending products in the area of cryopreservation and QC of stem cells.
She is as an advisor for the US Pharmacopoeia in standards setting for biologics and ancillary materials critical for the production of cellular therapies. She is a member of the BioFlorida Board of Directors, Board member of Business Development Board of Palm Beach County, Scientific Advisor for ISCT (International Society for Cell Therapy), Executive Committee Member for the Alliance of Regenerative Medicine and the Chair of the Business Advisory Board for the Banner Center of the State of Florida and is part of the organizing committee for the World Stem Cell Summit coming up in Palm Beach December 2012.
Excellence in Cell Based Assays
Excellent in cell based assays means lower research and development costs. There are two sides of the “cost coin”. On one side, if any of the raw materials (plates, cells, media, growth factors, markers, probes or detection, etc. are a weak link), the whole chain is destroyed and all time and material cost are wasted. On the other side, if culture conditions do not promote an environment enables in vivo like conditions, the data may prove to be unsupported in pre-clinical testing. This results in big costs in both opportunity and related expenses.
This is why Akron Biotech’s product and expertise are so important. This is also why they could become important partners for Neuromics. They have the ability to deliver a large cross section of the capabilities required for excellence in cell based assays.
These capabilities include:
- Best manufacturing practices (GMP) guarantee products will work as expected.
- Delivery of tools and methods that support research from the bench to pre-clinical studies.
- Product strategies that insure current and future fill known gaps in driving cell based assay excellence.
These includes: media, growth factors, 2D/3-D culturing ECMS and Polyfibers, recombinant proteins and cryopreservatives. Many fit hand in glove with my strategic offerings. I plan on continue to publishing update on new developments from Akron Biotech.